$243 Million is the total value of Aisling Capital Management LP's 17 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 18.8% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BBIO | BridgeBio Pharma Inc. (BBIO) | $160,016,456 | +53.3% | 6,068,125 | 0.0% | 65.94% | +29.0% | |
VRNA | Verona Pharma plc (VRNA)sponsored ads | $18,180,238 | -22.9% | 1,115,352 | 0.0% | 7.49% | -35.1% | |
SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $14,883,000 | -30.6% | 1,025,000 | 0.0% | 6.13% | -41.6% | |
BMEA | Biomea Fusion Inc (BMEA) | $10,990,896 | -37.3% | 798,757 | 0.0% | 4.53% | -47.3% | |
CMPS | New | Compass Pathways Plc (CMPS)sponsored ads | $7,137,000 | – | 964,500 | +100.0% | 2.94% | – |
GLUE | Monte Rosa Therapeutics Inc (GLUE) | $7,052,465 | -30.1% | 1,472,331 | 0.0% | 2.91% | -41.2% | |
RPHM | Reneo Pharmaceuticals Inc (RPHM) | $6,743,031 | +16.0% | 886,075 | 0.0% | 2.78% | -2.4% | |
NUVB | Nuvation Bio Inc. (NUVB) | $3,404,952 | -25.6% | 2,541,009 | 0.0% | 1.40% | -37.4% | |
ACRS | Aclaris Theraputics Inc (ACRS) | $2,976,017 | -33.9% | 434,455 | 0.0% | 1.23% | -44.4% | |
SPRB | Spruce Biosciences, Inc. (SPRB) | $2,724,455 | +5.1% | 1,205,511 | 0.0% | 1.12% | -11.6% | |
PSTX | Poseida Therapeutics Inc. (PSTX) | $2,482,975 | +35.2% | 1,043,267 | 0.0% | 1.02% | +13.8% | |
ELEV | Elevation Oncology Inc (ELEV) | $1,878,411 | -56.4% | 2,834,910 | 0.0% | 0.77% | -63.3% | |
AVRO | Avrobio, Inc. (AVRO) | $1,555,060 | +62.1% | 1,009,779 | 0.0% | 0.64% | +36.4% | |
Marker Therapeutics, Inc. (MRKR) | $1,426,857 | +46.5% | 314,286 | 0.0% | 0.59% | +23.3% | ||
New | Aeglea Biotherapeutics Inc (AGLE) | $828,652 | – | 67,645 | +100.0% | 0.34% | – | |
VIRX | Viracta Therapeutics Inc (VIRX) | $300,114 | -26.2% | 288,571 | 0.0% | 0.12% | -37.7% | |
BCEL | Atreca Inc. (BCEL) | $101,177 | -73.4% | 387,653 | 0.0% | 0.04% | -77.4% | |
AGLE | Exit | Aeglea Biotherapeutics Inc (AGLE) | $0 | – | -1,691,151 | -100.0% | -0.37% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-07 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-09 |
13F-HR | 2023-02-09 |
13F-HR | 2022-11-03 |
13F-HR | 2022-08-10 |
13F-HR | 2022-05-10 |
13F-HR | 2022-02-18 |
13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.